Day: January 26, 2022

HANOVER, MD., Jan. 26, 2022 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today released the following letter to shareholders from its Chief Executive Officer Dr. David Young. Dear Fellow Shareholder: As we start a new year, I want to thank you for your support and take this opportunity to share our accomplishments in 2021 and our planned path forward. We believe 2022 will be a transformative year for Processa as our multi-asset pipeline continues to mature and we achieve important clinical milestones. Our pipeline is different from that of other biotech companies because each of our drugs have a “de-risked”...

Conference Call is Tuesday, February 8, 2022 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, Wash., Jan. 26, 2022 (GLOBE NEWSWIRE) — Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call to discuss its financial results for the second quarter fiscal 2022 ended December 31, 2021 on Tuesday, February 8, 2022, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the second quarter fiscal year 2022 after the close of the U.S. stock markets on Tuesday, February 8, 2022. To listen to the conference call, please dial (888) 506-0062. For callers outside the U.S., please dial (973) 528-0011. The conference call will be simultaneously webcast and can be accessed at https://www.webcaster4.com/Webcast/Page/2199/44375...

AIM ImmunoTech management to participate in webinar Thursday, January 27th from 2:00 pm – 3:00 pm ET Company to discuss clinical plans for investigational drug Ampligen for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID OCALA, Fla., Jan. 26, 2022 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced it will participate in the Solve M.E. Diagnostics and Treatments Webinar: “Ampligen: A General Overview and the Plan for ME/CFS & Long Covid,” being held on Thursday, January 27, 2022 from 2:00 – 3:00 pm ET. Ampligen...

U.S. cybersecurity services firm promotes experienced operations professional SCOTTSDALE, Ariz., Jan. 26, 2022 (GLOBE NEWSWIRE) — Cerberus Cyber Sentinel Corporation (Nasdaq: CISO), a Managed Compliance and Cybersecurity Provider (MCCP) based in Scottsdale, Ariz., announced that Kyle Young has been promoted to executive vice president, operations. Young will be responsible for all business operations and work closely with CEO David Jemmett and CFO Deb Smith. Previously, Young served as vice president, operations, for Cerberus Sentinel. He has provided the operational due diligence on acquisitions, successfully integrating nine organizations into the company. He also has overseen the successful migration of the company and subsidiaries to NetSuite. Prior to joining Cerberus Sentinel in February 2021, Young served as vice president,...

– Company advancing diversified portfolio focused on areas of significant unmet medical need– Supported by solid financial position with cash to fund operations beyond 2023 TORONTO, ONTARIO, Jan. 26, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today provided a corporate update and business outlook. “Over the course of 2021, we in-licensed six new pre-clinical development programs, four potential therapeutics and two potential vaccines, all of which were added to our development pipeline based on their potential to represent significant individual market opportunities,” commented Dr. Klaus Paulini, Chief Executive Officer of Aeterna. “We...

Modern, high production volume facility supports Company’s growth plans and sustainability mission ROSH HA’AYIN, Israel, Jan. 26, 2022 (GLOBE NEWSWIRE) — Kornit Digital Ltd. (NASDAQ: KRNT), a worldwide market leader in sustainable, on-demand, digital fashionx and textile production technologies, announced today the official opening of its new scalable, state-of-the-art ink manufacturing facility in Kiryat Gat, Israel. The modern, 11,000-square-meter facility incorporates advanced automation, sophisticated workflows, and innovative technologies for production optimization. The new high-volume production facility is expected to fulfill global demand for Kornit consumables for the next decade. Recently completed at an estimated investment of $25 million USD, the facility was built in accordance with the highest quality, safety, and...

SAN FRANCISCO, Jan. 26, 2022 (GLOBE NEWSWIRE) — WalkMe Ltd. (NASDAQ: WKME), a leading provider of digital adoption solutions, today announced it will release its fourth quarter and full year 2021 financial results after U.S. markets close on Wednesday, February 16, 2022.   WalkMe will host a conference call and webcast that day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss its business and financial performance. Fourth Quarter and Full Year 2021 Financial Results and Conference Call Date: Wednesday, February 16, 2022 Time: 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time Webcast: https://ir.walkme.com Dial-in: US Toll Free: (800) 289-0720; International: +972 3376-2182; Passcode 7745495 Approximately one hour after completion of the live call, an archived version of the webcast will be available on the Company’s...

Figure 1Aparecida brownfield with projected vein extensions and surface and underground sampling results.Figure 2Esmeralda and Botella brownfields with projected vein extensions and surface and underground sampling results.Figure 3The main vein of Aurora with completed drill holes.TORONTO, Jan. 26, 2022 (GLOBE NEWSWIRE) — O2Gold Inc. (“O2Gold” or the “Company”) (TSXV: OTGO) is pleased to announce that a second campaign of ground geophysics has increased the overall projected vein extensions and identified three new veins in the brownfield targets of Aparecida, Esmeralda, and Botella. The Company has completed 4,000 meters of drilling, which has yielded an average grade of 7.44 g/t Au in Aurora. HighlightsSpontaneous potential ground geophysics increased the vein extensions in...

Genasys® National Emergency Warning System (NEWS) to Help Protect More than 5 Million Residents and Annual Visitors SAN DIEGO, Jan. 26, 2022 (GLOBE NEWSWIRE) — Genasys Inc. (NASDAQ: GNSS), the global leader in critical communications systems and solutions, today announced that Slovenia selected Genasys’ National Emergency Warning System (NEWS) to help keep more than 2 million residents and 3 million annual visitors safe and informed during emergencies and other critical events. Slovenia will deploy Genasys’ next generation NEWS software that supports and transmits Location-based SMS and Cell Broadcast alerts for regional and countrywide public warning. Slovenia will utilize NEWS to ensure the country meets the Article 110 European Electronic Communications Code requirements to implement and launch a comprehensive public...

Anti-tumor activity observed in fatty livers suggests rencofilstat may increase the treatment potential of anti-PD1 treatment in human liver cancer EDISON, N.J., Jan. 26, 2022 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), today announced the results of a nonclinical research study showing that its clinical phase drug candidate, rencofilstat (CRV431), synergistically decreased liver tumor growth and extended mouse survival when combined with an anti-PD1 antibody, an immune checkpoint inhibitor (“ICI”). The effects were observed in fatty livers, which may be associated with lower anti-PD1 efficacy...